Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8612789 | 0.85 | CNR2 (0.50) | ALDH1A1POLB | |
| SCHEMBL7712109 | 0.80 | CDC25A (0.56) | — | |
| SCHEMBL8186050 | 0.80 | ASH1L (0.47) | NR4A2KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL8613303 | 0.79 | MGAM (0.48) | KMT2AALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL27556048 | 0.79 | NR4A2 (0.36) | NR4A2KMT2AMEN1MAPTBRCA1 | |
| SCHEMBL8088590 | 0.78 | MEN1 (0.51) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL10396791 | 0.78 | NR4A2 (0.51) | NR4A2KMT2AMEN1MAPTBRCA1 | |
| SCHEMBL665932 | 0.78 | MEN1 (0.56) | NR4A2KMT2AMEN1MAPTBRCA1 | |
| SCHEMBL8527695 | 0.77 | KMT2A (0.40) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8181053 | 0.77 | CYP19A1 (0.54) | NR4A2KMT2AMEN1MAPTBRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6143932-A | FOR EFFECTING ANALGESIA, A DECREASE IN THE POSTPRANDIAL RISE IN THE BLOOD GLUCOSE LEVELS OF A MAMMAL AFTER INGESTION OF A CARBOHYDRATE LOAD BY SAID MAMMAL, AND TREATING MICROBIAL INFECTIONS | TREGA BIOSCIENCES, INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0890101-A4 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INST (US) | 1999-12-08 | — | — | EP | claimed |
| EP-0890101-A1 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1999-01-13 | — | — | EP | claimed |
| US-5859190-A | SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES | TREGA BIOSCIENCES, INC. (US) | 1999-01-12 | — | — | US | claimed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | claimed |
| WO-1997033174-A1 | SELECTIVELY N-ALKYLATED PEPTIDOMIMETIC COMBINATORIAL LIBRARIES AND COMPOUNDS THEREIN | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-09-12 | — | — | WO | claimed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | claimed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | claimed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | claimed |
| CN-1057269-A | Peptide compounds and preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-12-25 | — | — | CN | claimed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| CN-102369018-B | Treatment of diabetes and metabolic syndrome | 关键生物科学有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-7662849-B2 | Amidino compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1761485-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2006-11-23 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0552489-A2 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264464-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | NR4A2 4806/4885KMT2A 4394/4885MEN1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.